The World Health Organization (WHO) and the UN's Special Programme in Human Reproduction (HRP) is publishing the proposed membership of the Guideline Development Group for WHO's upcoming Recommendations on Expanding Contraception Options.
The Guideline Development Group is a group of experts external to WHO that will provide scientific advice and guidance to WHO on the technical content, organization, presentation and dissemination of these Recommendations. Members have been identified by the WHO Guideline Steering Group in collaboration with Regional Advisors for Sexual and Reproductive Health, and is composed of experts with extensive and diverse experience in family planning, contraception, public health, epidemiology, pharmacology, health systems, innovations and technology, nursing and midwifery, guideline development, research, etc.
The guideline development group will meet from 17–19 June 2025 at WHO's headquarters in Geneva to:
- appraise the evidence that will inform the development of the recommendations and formulate recommendations using a consensus-based approach;
- propose any outstanding research gaps; and
- highlight any implementation considerations.
The proposed group will provide recommendations on the efficacy, safety and acceptability of selected contraceptive methods that are registered and used in various countries, but not currently in the WHO Medical eligibility criteria for contraceptive use . It will also assess some contraceptive options that are used differently from the WHO Selected practice recommendations for contraceptive use .
The WHO normative meeting is by invitation only. In keeping with the requirements of the WHO Guidelines Review Committee and the WHO Compliance, Risk Management and Ethics Office, we are posting online short biographies of the guideline development group members. The listed candidates have also submitted a declaration of interest form stating any conflict of interests. WHO has applied its internal processes to ensure that the performance of the above tasks by members of this group will be transparent and without any significant conflict of interests (academic, financial or other) that could affect the credibility of the guideline.
In line with WHO policy on conflict of interest, the public and interested organizations can access the biographies of the guideline development group members
